Hims & Hers names ex-FDA official Deb Autor as first policy chief

Reuters
Nov 17, 2025
Hims & Hers names ex-FDA official Deb Autor as first policy chief

Nov 17 (Reuters) - Hims & Hers Health HIMS.N has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, the telehealth firm said on Monday.

Autor brings more than three decades of experience, having served as the deputy commissioner for global regulatory operations and policy at the U.S. Food and Drug Administration as well as having held a senior role in AstraZeneca AZN.L.

She has been a member of the Hims & Hers' board since last year, and will continue in that role.

Autor's appointment comes as Hims & Hers scales its engagement with regulators and policymakers, it said.

In September, Hims came under the FDA's scrutiny for what the agency called misleading marketing.

Hims has also shifted to selling "personalized" versions of semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, following the government's ban on the mass production of copies.

In the new role, Autor will collaborate with consumers, telehealth platforms, providers, pharmaceutical companies, policymakers, and regulators, Hims said.

(Reporting by Sneha S K in Bengaluru; Editing by Sahal Muhammed)

((Sneha.SK@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10